Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linezolid-induced peripheral neuropathy in a patient with multidrug-resistant pulmonary tuberculosis: a case report and comprehensive literature review.

Neurologia croatica : glasilo Udruzenja neurologa Jugoslavije = official journal of Yugoslav Neurological Association·2026
Same author

Application of a clinical scale for predicting Aβ-positivity in a multicentre Canadian dementia cohort: A necessity in the era of amyloid targeting treatment.

Journal of the neurological sciences·2026
Same author

A cross-vertebrate brain protein interaction map identifies conserved neural and non-neural complexes.

Cell reports·2026
Same author

A protein interactome for the last eukaryotic common ancestor illuminates the biochemical basis of modern genetic diseases.

Cell genomics·2026
Same author

Biases and consistency of different assay methods for neurological biomarkers using Quanterix single-molecule-array technology: A secondary analysis method comparison study.

NeuroMarkers·2026
Same author

Simoa and MSD platforms show analytical discordance but comparable diagnostic performance for GFAP, NF-L, and T-tau in adolescent concussion.

Scientific reports·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Jennifer G Cooper1, Nyra Ahmed1, Johnny Huang1

  • 1University of British Columbia, Vancouver, BC, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

血生物标志物对阿尔茨海默病 (AD) 病理检测具有很高的特异性. 然而,低灵敏度表明这些标志物可能低估了COMPASS-ND研究中的AD患病率.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物发现发现
  • 神经学 神经学

背景情况:

  • 神经退行和痴呆症综合评估 (COMPASS-ND) 研究是一项加拿大观察性研究,涉及患有痴呆症和认知投诉的参与者.
  • 这项研究利用了等离子体生物标记物,包括粉样β (Aβ42/40),酸化-181 (p-tau-181),神经丝光 (NfL) 和状纤维酸性蛋白质 (GFAP).
  • 这项研究旨在估计COMPASS-ND队列中阿尔茨海默病 (AD) 病理的流行率,并评估临床病理一致性.

研究的目的:

  • 用血生物标志物估计COMPASS-ND队列中阿尔茨海默病 (AD) 病理的流行率.
  • 评估临床诊断和潜在的AD病原体之间的一致性.
  • 建立血生物标志物的切断值,这些生物标志物表明AD病理.

主要方法:

  • 来自936名COMPASS-ND参与者的血样本使用Quanterix Simoa HD-X分析仪与神经学4-plex E和p-tau-181测定进行了分析.
  • 一个由150名具有脑脊液 (CSF) 数据的参与者组成的子队列被用来通过接受器操作曲线 (AUROC) 下面的区域分析来确定血生物标志物的切断点.
  • 已确定的切断线被应用于更大的队列,以估计不同诊断组中生物标志物阳性个体的百分比.

主要成果:

  • 已经确定了血生物标记的切线值:Aβ42/40 <0.068 pg/mL,p-tau-181 >2.7 pg/mL,NfL >18.6 pg/mL,以及GFAP >134.9 pg/mL.
  • 一个多生物标志物小组 (三分之二:Aβ42/40,p-tau-181,GFAP) 显示AD病理的敏感度为64%,特异性为83%.
  • 据估计,阿尔茨海默病理的患病率在诊断组之间有所不同,从主观认知障碍的25%到阿尔茨海默病的83%和勒维体痴呆症的83%.

结论:

  • 经测试的血生物标志物测试表明,在检测阿尔茨海默病 (AD) 病理方面具有很高的特异性.
  • 这些生物标志物可以用来估计AD病理的流行率在更大的队列.
  • 血生物标志物的低敏感性表明,在COMPASS-ND队列中潜在地低估了AD病理.